期刊文献+

两性霉素B持续椎管内给药治疗新型隐球菌性脑膜炎的脑脊液药动学监测 被引量:10

Pharmacokinetics of amphotericin B in the cerebrospinal fluid during continuous intrathecal administration for treatment of cryptococcal neoformans meningitis
下载PDF
导出
摘要 探讨两性霉素B(AMB)椎管内持续给药治疗新型隐球菌性脑膜炎的脑脊液药代动力学特点。方法 对3例新型隐球菌性脑膜炎患者进行了AMB椎管内持续给药疗法,用高效液相色谱法(HPLC)对其脑脊液(CSF)中AMB的药物浓度进行连续测定。结果 AMB椎管内持续给药后脑脊液中AMB的药物浓度大于AMB对新型隐球菌的最低抑菌浓度(MIC)。药-时曲线显示在开始进行AMB椎管内持续给药当天以及每次药物加量当天的AMB在CSF中的药物浓度出现较大波动,第二天处于稳定水平,AMB在CSF中的药物浓度维持在0.61~1.21 μg/ml。结论 椎管内持续给药能显著提高脑脊液中AMB浓度,而且能维持稳定有效的药物浓度,从而达到有效治疗的目的。 Objective To explore the pharmacokinetics of amphotericin B(AMB) in the cerebrospinal fluid(CSF) during continuous intrathecal administration of AMB for treatment of cryptococcal neoformans meningitis(CNM). Methods The concentration of AMB in the CSF was measured using reversed phase high performance liquid chromatography(RP-HPLC) in 3 patients receiving continuous intrathecal infusion of AMB for CNM.Results AMB concentrations in the CSF of the 3 patients exceeded the minimal inhibitory concentration(MIC) of AMB against Cryptococcus neoformans.The concentration-time curve showed that AMB concentration in the CSF underwent obvious variations on the first day of intrathecal infusion and after additional AMB doses,but maintained a stable level (0.61-1.21 μg/ml) on the next day.Conclution Continuous intrathecal administration of AMB can enhance the drug concentration in the CSF and maintain a stable and effective drug level for treatment of CNM.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2011年第11期1929-1931,共3页 Journal of Southern Medical University
基金 广东省科技计划项目(2007B031511011 2009B030801208)
关键词 新型隐球菌性脑膜炎 两性霉素B 椎管内持续给药 药代动力学 amphotericin B continuous intrathecal administration cryptococcal neoformans meningitis pharmacokinetics
  • 相关文献

参考文献4

二级参考文献28

  • 1王苏平,赵耿义,王虹.脑脊液置换配合鞘内给药治疗化脓性脑膜炎[J].中华急诊医学杂志,2007,16(1):54-56. 被引量:6
  • 2吕传真.神经系统感染性疾病[M].北京:人民军医出版社,2002.173-177. 被引量:26
  • 3Saag MS,Graybill RJ,Larsen RA,et al.Practice guidelines for the management of cryptococcal disease.Infectious Diseases Society of America.Clio Infect Dis,2000,30:710-718. 被引量:1
  • 4Yao Z,Liao W,Chen R.Management of cryptococcosis in non-HIV-related patients.Med Mycol,2005,43:245-251. 被引量:1
  • 5Trilles L,Fernandez-Torres B,Lazera Mdos S,et al.In vitro antifungal susceptibility of Cryptococcus gattii.J Clin Microbiol,2004,42:4815-4817. 被引量:1
  • 6Armengou A,Porcar C,Mascaro J,et al.Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptocoeeal meningitis.Clin Infect Dis,1996,23:1337-1338. 被引量:1
  • 7National Committee for Clinical Laboratory Standards.Reference method for broth dilution antifungal susceptibility testing of yeasts.Approved standard (M27-A2),2nd ed.Pennsylvania:National Committee for Clinical Laboratory Standards,2002. 被引量:1
  • 8Espinel-lngroff A,Canton E,Gibbs D,et al.Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp.and Cryptococcus neoformans to amphotericin B,caspofungin,fluconazole,itraconazole,and voriconazole.J Clin Microbiol,2007,45:858-864. 被引量:1
  • 9Yildiran ST,Fothergill AW,Sutton DA,et al.In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole,voriconazole and posaconazole (SCH56592).Mycoses,2002,45:378-383. 被引量:1
  • 10Sarosi GA,Amphotericin B.Still the gold standard for antigungal therapy[J].Postgrad Med,1990,88(7):151. 被引量:1

共引文献359

同被引文献76

引证文献10

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部